EyeWorld Korea June 2019 Issue

62 EWAP JUNE 2019 GLAUCOMA ࢶഋഥӈ ࠙ࢳ Ѿҗ ѐ੄ $-4 ݒ ѐ߸ࣻী ੓যࢲ ׮ܲ ف о૑ ઺੤ࣿ ࠁ ׮ ੺ѐࣻࣿ੉ ਬ੄޷ೞѱ ખ ؊ ബҗ੸੉঻׮ ࣻࣿ੉ $-4 TJHOBMٜਸ о੢ ௾ ࠺ਯ ߸ ۽ ചदః ח Ѫਵ ۽ ৘ஏ غ ঻׮ ೠ $-4 ݒ ѐ߸ࣻ੄ ҃਋ ۨ੉੷ ࢻਬ઱ࢿഋࣿ੉ Ҵࣗ উ঑ъೞઁ ࠁ ׮ ਬ੄޷ೞѱ ખ ؊ ബҗ੸ੋ Ѫਵ ۽ աఋլ׮ t੺ѐ ֣ղ੢ ࣻࣿ਷ ۨ੉੷ ࢻਬ઱ࢿഋࣿ ߂ ֣ղ੢ড ࠁ ޛ ׮ ("5 ߂ दр $-4 ݒ ѐ߸ࣻী ੓য ખ ؊ ഛোೠ ৔ೱਸ ઱঻ण פ ׮ ૊ ࣻࣿ ۨ੉੷ ড ޛ ࣽਵ ۽ ബҗо ੓঻؍ Ѫ੉ભ ࣻࣿ੄҃਋ ࣻࣿ റ ࣽ਽ חب ௾ ޙ ઁо غ ૑ ঋण פ ׮u %S $VUPMP о ݈ਸ ੉঻׮ t$-4 ח ઱р ("5 *01 ࠁ ׮ *01 ܳ ծ୶ ח ઺੤ࣿী ੄ೠ ಁఢ੄ ߸ചܳ ؊਌ ੜ х૑೧յ ࣻ ੓ਵ ݴ ੉ ੢࠺ ח ੐࢚ജ҃ীࢲ *01ܳ ծ୶ ח ઺੤ࣿ੄ ஖ ܐ ബҗ৬ ੐࢚ Ѿҗܳ ಣоೞ ח ؘ ب ਑ਸ ઴ ࣻ ੓ण פ ׮ ݽ ٚ ઺੤ࣿী ੓য ঠр $-4 ಁఢ੉ ઁੌ ޹х೮ण פ ׮ u दр $-4ܳ Ѣ஘ ֣ղ੢੉ ஖ ݺ ػܐ ੄ ജ੗ٜਸ ؀࢚ਵ ۽ ૓೯ೞৈ ੉੹ী ߊ ಴ غ ঻؍ %F .PSBFT FU BM੄ োҳѾҗী ٮ ܰ ݶ दঠ ૓೯ WJTVBM GJFME QSPHSFTTJPO ਷ $-4 ӝ ۾ җ োҙࢿਸ ࠁ ৓׮Ҋ ೠ׮ ࣻ ݶ ઺੄ MPOH QFBL ੄ ࣻ ӒܻҊ ജ੗о ӵয੓ਸ ٸ ੄ ಣӐ QFBL SBUJPо ࡅ ܲ ૓೯੄ о੢ જ਷ ৘ஏੋ੗৓׮ $-4 ݒ ѐ߸ٜࣻ੄ ઑ೤਷ э਷ ӝр ղী ஏ੿ೠ Ҏ٘݅঑ಣউ঑҅ (PMENBOO BQQMBOBUJPO *01 ݒ ѐ߸ࣻ ಣӐ ೖ௼ ߸ ࠁ ز ׮ ա਷ ஏ੿஖ܳ ઁҕ೧઱঻׮ ਤ৬ ޖ ҙೠ ੐࢚द೷ীࢲ োҳ૓ٜ਷ *01৬ ҙ۲ ػ ಁఢਸ פݽ ఠ݂ ೞҊ ੐࢚੄о ࢎਊೡ ࣻ ੓ * ח 01 ੿ ࠁ ܳ ևഃષী ੓য ౟ܻѢೖए 5SJHHFSGJTI ࣻद ۽ উ঑ਸ ஏ੿ೞৈ ݅ੌ ޙ ઁо ߊ ࢤೡ ҃਋ ޖ ࢶ ࣻनӝܳ ా೧ ੄ ܐ ૓ীѱ ੹׳ೞ ߑ ח ध $-4о উ੹ೞҊ ੜ ਊੋ ߑ חغ ध੉ חۄ Ѫਸ ߋ ഃչਵ ݴ ೧׼ োҳীࢲ ঳਷ ੿ ࠁ ٜ੉ Ҋਤ೷ ജ੗ܳ ध߹ೞҊ ઺੤ࣿী ؀ೠ ஖ ܐ ߈ ਽ਸ פݽ ఠ݂ ೞ ח ؘ ӟਃೞѱ ॳੌ Ѫ੉ ۄ Ҋ ࢤпೞҊ ੓׮ EWAP References £° i œÀ>ià ] iÌ >° 6ˆÃÕ> wi` V…>˜}i >˜` Ó{‡…œÕÀ "*‡Ài>Ìi` «Àœwi with a contact lens sensor in treated glaucoma patients. Ophthalmol . 2016;123:744–53. 2. De Moraes CG, et al. Association between 24-hour intraocular pressure monitored with contact lens sensor and ۈÃÕ> wi` «Àœ}ÀiÃȜ˜ ˆ˜ œ`iÀ >`ՏÌà with glaucoma. JAMA Ophthalmol . 2018;136:779–785. 3. Dunbar GE, et al. The Sensimed /Àˆ}}iÀwÅVœ˜Ì>VÌ i˜Ã Ãi˜ÃœÀ\ ivwV>VÞ] safety, and patient perspectives. Clin Ophthalmol. 2017;11:875–882. ੺ѐ ੹ী ੉धೡ ਤ஖ܳ ࢎ੹ী ҅ദ೧ ۄف Ҋ ࣿ੗ٜীѱ ઑ঱ೞ৓׮ ప֤խ੉ ࢚ҕ݄ী ࠢ૑ ঋ ۾ب ೞҊ Ѿ݄ೞ ҕрਵ ۽ ੽Ӕೡ ٸ ઱ࢎ ۽ט߄ ੋೠ ୌҕ੉ ߊ ࢤೞ૑ ঋ ۾ب ਬ੄ೞ ח Ѫ੉ ઺ਃೞ׮Ҋ ೞ৓׮ ژ ೠ Ӓ ח Ѿ݄ೞ ҕрਵ ۽ ੄ ઱ࢎ ט߄ ੽Ӕਸ ߑ ೧ೞ ח ୹ആ੄ ਤ೷ਸ ઴੉ӝ ਤ೧ Ѿ݄ ആҙ੉ হ ח ࠗਤী ࣻࣿ ࠗਤܳ ݃ఊೠ׮Ҋ ೠ׮ ੹ ߑ ীٜযт ٸ ठܻ࠳੷೦ TMFFWF SFTJTUBODF ੉ ޙ ઁܳੌਵఆ ࣻ੓ਵ ݴ ۪ૉ੄࢚ࣚਸ ߑ ૑ೞӝ ਤ೧ QIBLJD FZFীࢲ ח ઱੄ܳ ӝ਎ৈঠೠ׮ҊӒ ח ࢸ ݺ ೮׮ Ӓ੄҃਋ ࣻࣿ੹ QIBLJD FZF ীQJMPDBSQJOF ESPQਸࢎਊೞৈ ੉۞ೠਤ೷ٜਸ୭ࣗചೠ׮ Ӓ ח ੹ ߑ пਵ ט߄۽ ਸ઱ੑೡ ٸ ֫ѱ ӒܻҊডрখଃਸ 9&/झబ౟ ੉ध੄ प۹ ߂ ࣿറ ౲ GSPN QBHF ೱೞѱ ט߄ ਸ ك ׮ ੼఍ ޛ ૕੉ ੹ ߑ ਸ࢚׼൤Өѱٜ݅ӝ ޙٸ ী ੹ ߑ п҃Ѩࢎ۪ૉ HPOJPTDPQZ MFOT ܳా೧૒੽ ݶࠁ ࢲदࣿೞ૑ ঋ ח ҃਋ ੹ ߑ п੄೧ࠗҳઑী ؀ೠࣿ੗੄౸ ױ ੉൒۰૑ѱ ؼ ࣻ੓׮ ݃૑݄ਵ ۽ ݅ੌ җ ب ೞѱറ ߑ ਵ ۽ ઱ੑ ݴغ 9&/੉ ഘ଻ӔࠗীٜযоѢաഘ଻ীց ޖ оӰѱ੽Ӕೞѱ غ য UJQ੉݄൧ ࣻо੓׮ Ӓ ח উҗ੄ٜীѱ੹୓߬߰ GVMM CFWFM ੉ ࠁ ੌ ٸ ө૑ ט߄ ਸҕ݄ উଃਵ ۽ ૓೯दః زח উ౟ ۑ ࣌ USBDUJPO ਸࢎਊೞҊ ठ ۄ ੉؊੄ о߶਍ زߊ ੘ਊ BDUVBUJPO ਸ ా೧झబ౟ܳ੉धೡ ٸ ౟ ۑ ࣌ਸ ઁѢೞҊ JOKFDUPS ۽ ডрখଃਵ ۽ ঑۱ਸ઱Ҋ੓ਸѪਸӂਬ೮׮ EWAP References 1. Grover DS, et al. Performance and safety of a new ab interno gelatin stent in refractory glaucoma at 12 months. Am J Ophthalmol . 2017;183:25–36. Ó° -V…i˜ŽiÀ ] iÌ >° vwV>VÞ] safety, and risk factors for failure of standalone ab interno gelatin microstent implantation versus standalone trabeculectomy. Ophthalmol . 2017;124:1579–1588.